0001910594-22-000013.txt : 20220919 0001910594-22-000013.hdr.sgml : 20220919 20220816135121 ACCESSION NUMBER: 0001910594-22-000013 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Facible BioDiagnostics, Inc. CENTRAL INDEX KEY: 0001910594 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 882039154 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 366 SW 5TH AVE STREET 2: STE 104 CITY: MERIDIAN STATE: ID ZIP: 83642 BUSINESS PHONE: 8013616686 MAIL ADDRESS: STREET 1: 366 SW 5TH AVE STREET 2: STE 104 CITY: MERIDIAN STATE: ID ZIP: 83642 FORMER COMPANY: FORMER CONFORMED NAME: FACbile BioDiagnostics LLC DATE OF NAME CHANGE: 20220210 CORRESP 1 filename1.htm

VIA EDGAR

 

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street,

 NE Washington, D.C. 20549

 

 

 

August 16, 2022

 

 

 


Re:Facible BioDiagnostics, Inc.

Post Qualification Amendment No. 1 to Offering Statement on Form 1-A

File No. 024-11878

 

 

 

 

 

 

To Whom It May Concern:

 

 

On behalf of Facible BioDiagnostics, Inc. (the “Company”), I hereby request qualification of the above-referenced amended offering statement at 2:00PM, Eastern Time, on Friday, August 19, 2022, or as soon thereafter as is practicable.

 

 

Sincerely,

 

 

 

 

/s/ Dr. Steven Burden, Ph.D.

 

 

 

 

Dr. Steven Burden, Ph.D.

 

Director, Chief Executive Officer, President

 

 Facible BioDiagnostics, Inc.